Free Trial
NYSE:ALC

Alcon (ALC) Stock Price, News & Analysis

Alcon logo
$89.56 +0.00 (+0.00%)
Closing price 02/20/2025 03:59 PM Eastern
Extended Trading
$90.30 +0.74 (+0.83%)
As of 09:12 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Alcon Stock (NYSE:ALC)

Key Stats

Today's Range
$88.56
$89.61
50-Day Range
$82.70
$93.55
52-Week Range
$77.54
$101.10
Volume
867,807 shs
Average Volume
1.50 million shs
Market Capitalization
$44.18 billion
P/E Ratio
38.27
Dividend Yield
N/A
Price Target
$102.38
Consensus Rating
Moderate Buy

Company Overview

Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system, ARGOS biometer, LuxOR surgical ophthalmic microscope, SMARTCATARACT health platform, NGENUITY 3D visualization system, Verion reference unit and Verion digital marker, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; EX-PRESS glaucoma filtration device; and implantable products, including AcrySof IQ products, such as monofocal IOLs and advanced technology IOLs for the correction of presbyopia and astigmatism at the time of cataract surgery. Its Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, glaucoma, contact lens care, and ocular allergies; and ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.

Alcon Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
42nd Percentile Overall Score

ALC MarketRank™: 

Alcon scored higher than 42% of companies evaluated by MarketBeat, and ranked 626th out of 954 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Alcon has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 12 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Alcon has only been the subject of 4 research reports in the past 90 days.

  • Read more about Alcon's stock forecast and price target.
  • Earnings Growth

    Earnings for Alcon are expected to grow by 8.58% in the coming year, from $3.03 to $3.29 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Alcon is 38.27, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 21.39.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Alcon is 38.27, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 16.33.

  • Price to Earnings Growth Ratio

    Alcon has a PEG Ratio of 2.27. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Alcon has a P/B Ratio of 2.14. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Alcon's valuation and earnings.
  • Percentage of Shares Shorted

    0.66% of the float of Alcon has been sold short.
  • Short Interest Ratio / Days to Cover

    Alcon has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Alcon has recently decreased by 1.53%, indicating that investor sentiment is improving.
  • Dividend Yield

    Alcon does not currently pay a dividend.

  • Dividend Growth

    Alcon does not have a long track record of dividend growth.

  • Dividend Sustainability

    Based on earnings estimates, Alcon will have a dividend payout ratio of 7.90% next year. This indicates that Alcon will be able to sustain or increase its dividend.

  • Percentage of Shares Shorted

    0.66% of the float of Alcon has been sold short.
  • Short Interest Ratio / Days to Cover

    Alcon has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Alcon has recently decreased by 1.53%, indicating that investor sentiment is improving.
  • News Sentiment

    Alcon has a news sentiment score of -0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Alcon this week, compared to 4 articles on an average week.
  • Search Interest

    Only 8 people have searched for ALC on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.
  • MarketBeat Follows

    Only 2 people have added Alcon to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Alcon insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 1.52% of the stock of Alcon is held by insiders.

  • Percentage Held by Institutions

    53.86% of the stock of Alcon is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Alcon's insider trading history.
Receive ALC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alcon and its competitors with MarketBeat's FREE daily newsletter.

ALC Stock News Headlines

Alcon debuts Voyager DSLT for glaucoma and ocular hypertension treatment
This simple indicator removes the “technical” out of technical trading
Experts are calling it the best buy/sell indicator of 2024… A finance whiz from northern Florida has coded an indicator that isolates the precise dates to buy in and out of the stock market. According to the creator, it allows him to ride all the market highs yet sidestep the lows. And for the first time ever, he’s sharing his indicator with the public. As you’ll see in today’s free trading session, you simply buy when the candles turn green and sell when they turn red.
Alcon (ALC) Receives a Hold from Kepler Capital
See More Headlines

ALC Stock Analysis - Frequently Asked Questions

Alcon's stock was trading at $84.89 at the beginning of 2025. Since then, ALC stock has increased by 5.5% and is now trading at $89.5610.
View the best growth stocks for 2025 here
.

Alcon Inc. (NYSE:ALC) posted its earnings results on Tuesday, November, 12th. The healthcare company reported $0.81 EPS for the quarter, topping the consensus estimate of $0.72 by $0.09. The healthcare company had revenue of $2.45 billion for the quarter, compared to analyst estimates of $2.45 billion. Alcon had a trailing twelve-month return on equity of 7.17% and a net margin of 11.89%.

Alcon subsidiaries include Alcon (China) Ophthalmic Product Co. Ltd., Alcon Finance Corporation, Alcon Japan Ltd., Alcon Laboratories Inc., Alcon Pharmaceuticals Ltd., Alcon Research LLC, and Alcon Vision LLC.

Top institutional investors of Alcon include Vanguard Group Inc. (3.97%), FMR LLC (3.04%), Norges Bank (2.56%) and UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC (2.42%).

Shares of ALC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Alcon investors own include Coca-Cola (KO), AT&T (T), Walt Disney (DIS), PepsiCo (PEP), Verizon Communications (VZ), Cisco Systems (CSCO) and Johnson & Johnson (JNJ).

Company Calendar

Last Earnings
11/12/2024
Today
2/21/2025
Next Earnings (Estimated)
5/08/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Ophthalmic goods
Sub-Industry
Health Care Facilities
CUSIP
04544X30
Employees
25,000
Year Founded
1945

Price Target and Rating

Average Stock Price Target
$102.38
High Stock Price Target
$110.00
Low Stock Price Target
$85.00
Potential Upside/Downside
+14.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
14 Analysts

Profitability

Net Income
$974 million
Pretax Margin
11.01%

Debt

Sales & Book Value

Annual Sales
$9.46 billion
Cash Flow
$5.24 per share
Book Value
$41.81 per share

Miscellaneous

Free Float
485,747,000
Market Cap
$44.18 billion
Optionable
Optionable
Beta
0.99

Social Links

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NYSE:ALC) was last updated on 2/21/2025 by MarketBeat.com Staff
From Our Partners